Related Experiment Video
Updated: May 23, 2026

Characterization of pH-Dependent Reversible Self-Assembly of Amyloid Beta 1-40-Coated Gold Colloids
Published on: March 21, 2025
Dimer formation enhances structural differences between amyloid β-protein (1-40) and (1-42): an explicit-solvent
1Physics Department, Drexel University, Philadelphia, Pennsylvania, United States of America.
Abstract:
Amyloid β-protein (Aβ) is central to the pathology of Alzheimer's disease. A 5% difference in the primary structure of the two predominant alloforms, Aβ(1-40) and Aβ(1-42), results in distinct assembly pathways and toxicity properties. Discrete molecular dynamics (DMD) studies of Aβ(1-40) and Aβ(1-42) assembly resulted in alloform-specific oligomer size distributions consistent with experimental findings. Here, a large ensemble of DMD-derived Aβ(1-40) and Aβ(1-42) monomers and dimers was subjected to fully atomistic molecular dynamics (MD) simulations using the OPLS-AA force field combined with two water models, SPCE and TIP3P. The resulting all-atom conformations were slightly larger, less compact, had similar turn and lower β-strand propensities than those predicted by DMD. Fully atomistic Aβ(1-40) and Aβ(1-42) monomers populated qualitatively similar free energy landscapes. In contrast, the free energy landscape of Aβ(1-42) dimers indicated a larger conformational variability in comparison to that of Aβ(1-40) dimers. Aβ(1-42) dimers were characterized by an increased flexibility in the N-terminal region D1-R5 and a larger solvent exposure of charged amino acids relative to Aβ(1-40) dimers. Of the three positively charged amino acids, R5 was the most and K16 the least involved in salt bridge formation. This result was independent of the water model, alloform, and assembly state. Overall, salt bridge propensities increased upon dimer formation. An exception was the salt bridge propensity of K28, which decreased upon formation of Aβ(1-42) dimers and was significantly lower than in Aβ(1-40) dimers. The potential relevance of the three positively charged amino acids in mediating the Aβ oligomer toxicity is discussed in the light of available experimental data.
Insights
Alzheimer's disease research reveals distinct molecular behaviors between Amyloid β-protein (Aβ) alloforms Aβ(1-40) and Aβ(1-42). These differences in dimer flexibility and charged amino acid interactions may explain varying Aβ oligomer toxicity.
Area of Science:
- Biochemistry
- Computational Biology
- Neuroscience
Background:
- Amyloid β-protein (Aβ) aggregation is central to Alzheimer's disease (AD) pathology.
- The two main alloforms, Aβ(1-40) and Aβ(1-42), exhibit distinct assembly and toxicity due to a 5% structural difference.
Purpose of the Study:
- To investigate the molecular dynamics and conformational differences between Aβ(1-40) and Aβ(1-42) dimers.
- To explore the role of charged amino acids in Aβ alloform assembly and potential toxicity.
Main Methods:
- Utilized Discrete Molecular Dynamics (DMD) for initial studies.
- Employed fully atomistic Molecular Dynamics (MD) simulations with OPLS-AA force field and SPCE/TIP3P water models.
- Analyzed free energy landscapes, conformational variability, and salt bridge formation.
Main Results:
- Atomistic simulations showed larger, less compact conformations than DMD predictions.
- Aβ(1-42) dimers exhibited greater conformational variability and N-terminal flexibility than Aβ(1-40) dimers.
- Salt bridge formation increased with dimerization, with notable differences in K28 propensity between alloforms.
Conclusions:
- Aβ(1-42) dimers display increased flexibility and solvent exposure of charged residues compared to Aβ(1-40).
- Specific charged amino acid interactions (e.g., R5, K28) differ between alloforms and may influence oligomer toxicity.
- Findings provide molecular insights into alloform-specific Aβ assembly relevant to Alzheimer's disease pathogenesis.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Protein Folding

